Valuation — not yet established
No valuation for RayzeBio is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($372.8M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 4 rounds
- ·Watchlist + deal alerts for RayzeBio
Create free account
No card required
Funding history
4 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Sep 2022 | Later Stage VC (Series D) | $159.8M | ▮ | ▮ |
| Jun 2021 | Later Stage VC (Series C) | $108.0M | ▮ | ▮ |
| Nov 2020 | Early Stage VC (Series B) | $105.0M | ▮ | ▮ |
| Aug 2020 | Early Stage VC | $15.0M | ▮ | ▮ |
How RayzeBio's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For RayzeBio, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has RayzeBio raised?
- RayzeBio has raised $372.8M in total funding across 4 recorded rounds.
- When did RayzeBio last raise?
- RayzeBio last raised in Sep 2022 (Later Stage VC (Series D)), raising $159.8M.